Aclarion, Inc. has established a commercial agreement with Weill Cornell Medicine to bring its Nociscan technology to the institution's spine research program. The agreement enables the use of Nociscan in a clinical trial entitled "A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease," which is investigating how the dose and quantity of bone marrow aspirate stem cell concentrate affects patient-reported functional outcomes and pain when treating osteoarthritis and degenerative disc disease in the spine.
The trial will be conducted at Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center under the leadership of Jaspal Ricky Singh, MD, Vice Chair and Director of Interventional Spine at Weill Cornell Medicine. A subset of spine patients selected through Dr. Singh's clinical evaluation will be eligible for Nociscan assessment as part of the research. Dr. Singh noted that his team's comprehensive approach to treating spinal disorders, which includes physical therapy and various interventional techniques, creates an ideal opportunity to utilize the insights provided by Nociscan in their pioneering research into discogenic low back pain and concentrated bone marrow aspirate treatments.
This collaboration is significant because chronic low back pain represents a global healthcare problem affecting approximately 266 million people worldwide who suffer from degenerative spine disease and low back pain. Nociscan is positioned as the first evidence-supported Software-as-a-Service platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology objectively quantifies chemical biomarkers demonstrated to be associated with disc pain, and when used with other diagnostic tools, can provide critical insights into the location of a patient's low back pain.
The integration of Nociscan into this research trial at a prestigious medical institution like Weill Cornell Medicine represents an important validation of the technology's potential clinical utility. By participating in research investigating stem cell treatments for degenerative spine conditions, Nociscan could help establish more precise treatment protocols and contribute to improved patient outcomes. The technology operates by receiving magnetic resonance spectroscopy data from MRI machines through a cloud connection, where proprietary signal processing techniques extract and quantify chemical biomarkers associated with disc pain. This biomarker data is then analyzed through proprietary algorithms to indicate whether a disc may be a source of pain.
For more information about Aclarion and its technology, please visit https://www.aclarion.com. The company's latest news and updates are available through their newsroom at https://tinyurl.com/aconnewsroom. This research collaboration represents a meaningful step toward addressing the substantial global burden of chronic low back pain through innovative diagnostic technologies that can potentially guide more effective treatment strategies for patients suffering from degenerative spine conditions.
